LOTUSATE
LOE ApproachingNDAORALTABLET
Approved
Sep 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTUSATE is an oral tablet small molecule NDA approved in 1954 by Sanofi. The generic name and mechanism of action are not publicly disclosed in available data. Patient population and therapeutic indication cannot be determined from current information.
LOE Approaching
This legacy product is approaching loss of exclusivity with low competitive pressure (30/100), signaling a contracting team and defensive commercial strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect a stagnant product with minimal hiring activity. Working on LOTUSATE offers limited career advancement and exposure to modern pharma practices. This is a legacy asset best suited for cost-management or divestment planning roles.
Brand ManagerField Sales
Worked on LOTUSATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.